Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 4/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20134858 | 0.84 | KMT2A (0.55) | RECQLSTSPTPN2PTPN1PTPN6 | |
| SCHEMBL12919132 | 0.81 | PTPN2 (0.49) | RECQLSTSPTPN2PTPN1PTPN6 | |
| SCHEMBL17827895 | 0.78 | KMT2A (0.50) | RECQLSTSPTPN2PTPN1PTPN6 | |
| SCHEMBL10180063 | 0.78 | GPR119 (0.59) | DDB1CRBNHPGDGPR119KMT2A | |
| SCHEMBL19172709 | 0.77 | PTPN2 (0.72) | RECQLSTSPTPN2PTPN1PTPN6 | |
| SCHEMBL28579701 | 0.77 | SYK (0.46) | RECQLDDB1CRBNGPR119NAMPT | |
| SCHEMBL406827 | 0.76 | GPR119 (0.62) | STSPTPN2PTPN1PTPN6HPGD | |
| SCHEMBL12367648 | 0.76 | TACR3 (0.41) | NAMPT | |
| SCHEMBL1698741 | 0.76 | GPR119 (0.60) | DDB1CRBNPTPN2PTPN1PTPN6 | |
| SCHEMBL25093627 | 0.75 | DDB1 (0.58) | DDB1CRBNSTSPTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | PALANI ANANDAN | 2011-08-25 | — | — | US | disclosed |
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | PALANI ANANDAN | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | AZI2, GPR119, GID4 | RECQL 3222/4885DDB1 3926/4885CRBN 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.